Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Berruti
Alfredo
A
Tucci
Marcello
M
Terrone
Carlo
C
Scarpa
Roberto Mario
RM
Angeli
Alberto
A
Dogliotti
Luigi
L
D000469:Alkaline Phosphatase / Q000187:drug effects / Q000378:metabolism*; D000728:Androgens / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism* / Q000556:secondary; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D000077211:Zoledronic Acid
D000728:Androgens; D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D010281:Parathyroid Hormone; D000077211:Zoledronic Acid; D000469:Alkaline Phosphatase